ClinicalTrials.gg
RecruitingNCT06997965MIRIADUpdated Oct 26, 2026

Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD

A Phase 4 interventional study of Mirikizumab in Crohn Disease, sponsored by Alimentiv Inc.. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Alimentiv Inc. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 26, 2026Primary outcomes revisedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.

Planned enrollment
9th of 10
60 · median 150
Started
2026
with 3 others
Phase 4
5 of 10
5 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Alimentiv Inc.

Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 9th largest by planned enrollment, is one of 4 that started in 2026, is one of 5 in phase 4, and was the 6th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing mirikizumab in Crohn Disease, or all of them as a file.
02

Study summary

This is an open-label, single-arm, phase 4 study to assess the safety and efficacy of mirikizumab in approximately 60 participants with stricturing CD.

Read the detailed description

This is an open-label, single-arm, phase 4 study to assess the efficacy of mirikizumab in 18 years of age) with a diagnosis of ileal or ileocolonic CD based upon radiologic, clinical, endoscopic, and histologic evidence with tolerable obstructive symptoms. Participants will be recruited from approximately 25 sites in 3 countries (Canada, the United Kingdom [UK] and the United States [US]).

This study consists of 3 study periods (screening period, open-label treatment period, and safety follow-up). After signing informed consent, potential study participants will be screened over a 5- week screening period, including magnetic resonance enterography (MRE) and ileocolonoscopy to confirm the presence of inflammatory strictures. Eligible participants will receive 900 mg mirikizumab intravenously (IV) on Day 1 every 4 weeks (Q4W) to Week 8, and then 300 mg mirikizumab subcutaneously (SC) Q4W from Week 12 to Week 24. The primary endpoint will be assessed at Week 24.

During the screening visit, MRE will be used to confirm the presence of stricture with areas of edema, which represents a specific sign of moderate-to-severe histologic inflammation. Edema appears as areas of high signal intensity on T2 sequences with selective fat suppression.

During screening and Week 24 visits, participants will undergo blinded MRE disease activity assessment with the MaRIA and simplified MaRIA (sMaRIA) score and assessment of stricture items. At the same time points, ileocolonoscopy with biopsy collection (2 from the ileum and 2 from each of ascending, transverse, and descending colon and rectum segments, and 2 within [if feasible] or as close to the stricture of the terminal ileum as possible; 12 biopsies total) will be performed for blinded endoscopic and histopathologic disease activity assessments with the SES- CD and Robarts Histopathology Index (RHI), respectively.

Throughout the study, participants will undergo routine safety assessments at clinic visits, which will include physical examination, clinical laboratory assessment, and recording of serious adverse events (SAEs). At specified time points throughout the study, participants will complete patient-reported items of the CDAI/2-item PRO (PRO2)/ Harvey-Bradshaw Index (HBI), CD Obstructive Score (CDOS), stricture symptom-related questions, fecal Urgency Numerical Rating Scale (UNRS), Patient Global Impressions of Severity (PGI-S), PGI of Change (PGI-C), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and Symptoms and Impacts Questionnaire for CD (SIQ-CD) questionnaires in an electronic study diary for 7 days. Blood samples will be collected during screening and at Weeks 12 and 24 for safety laboratory and C-reactive protein (CRP) assessments. Stool samples will be collected at baseline and Week 24 for assessing fecal calprotectin (FCP) levels.

Participants will undergo a safety follow-up visit 4 weeks after the last dose of study treatment for safety assessments and recording of SAEs, severe liver injury (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] 3 × upper limit of normal [ULN]), serious infections, and CD- related complications. The safety follow-up visit can be performed by telephone, unless the participant has any ongoing AEs that require follow-up assessment.

03

Conditions studied

  • Crohn Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Nonpregnant, nonlactating adults, ≥ 18 years of age.
  2. Diagnosis of ileal or ileocolonic CD based on standard clinical, endoscopic, and histologic evidence; established at least 3 months prior to screening.
  3. Presence of at least 1 inflammatory stricture in the terminal ileum* within reach of an endoscope (passable or nonpassable). Strictures should be noncritical, naïve or anastomotic stricture(s), caused by CD and confirmed centrally by MRE according to the following criteria:

    • Localized luminal narrowing (luminal diameter ≤ 50% relative to normal adjacent bowel); AND
    • Bowel wall thickening (≥ 25% relative to adjacent bowel; AND
    • Either prestenotic dilation (defined as a luminal diameter ≥ 3 cm) or nonpassable with adult colonoscope *Note: The terminal ileum is defined as the last 15 cm of ileum proximal to the ileocecal valve or ileocolonic anastomosis. Other small bowel strictures will be considered on a case-by-case basis following discussion with the sponsor. Two strictures within 3 cm are considered the same stricture, and a long segment with multiple areas of narrowing or multiple strictures, that have inflammation between them, is counted as 1 stricture.
  4. Abdominal pain after eating and/or limitations in the amount/types of food eaten.
  5. Presence of tolerable obstructive symptoms and not expected to require hospitalization, endoscopic balloon dilation, surgical resection, or additional therapy during the study period. Participants should have sufficient food intake, even with diet modification, defined as a stable weight over 4 weeks prior to initiation of study intervention.
  6. Participants taking oral (eg, ≤ 20 mg/day prednisone or ≤ 9 mg/day budesonide) for ≥ 4 weeks prior to screening. Participants must be willing to undergo corticosteroid taper 8 weeks after initiation of study intervention as per standard of care.
  7. Participants can be on stable background therapy for CD and must agree to maintain the background therapy during the study. Acceptable stable background therapies include:

    • Oral 5-ASA drugs or sulfasalazine ≤ 4.8 g per day, for ≥ 4 weeks prior to screening
    • AZA, 6-MP, or MTX for ≥ 4 weeks prior to Screening
    • Any rectal therapy for treatment of CD for ≥ 4 weeks prior to screening
    • Antidiarrheal drugs for ≥ 8 weeks prior to screening
    • Bile acid sequestrants for ≥ 4 weeks prior to screening
  8. use by study participants should be in accordance with the mirikizumab product monograph and local guidelines.
  9. Signed .

Exclusion criteria

Exclusion Criteria:

  1. History or current diagnosis of UC, indeterminate colitis, ischemic colitis, nonsteroidal anti inflammatory drug-induced colitis, idiopathic colitis (ie, colitis not consistent with CD), radiation colitis, microscopic colitis, colonic mucosal dysplasia, or untreated bile acid malabsorption.
  2. CD-related complications:

    • Previous extensive small bowel resection, ileorectal anastomosis, or a proctocolectomy, with no more than 2 segments missing.
    • Short bowel syndrome.
    • Ileostomy (diverting or end), colostomy, small bowel stoma, or ileoanal pouch.
    • Inactive fistulae in or adjacent to an ileal stricture. Participants with perianal fistulae could be included provided there is no evidence of peri-anal abscess > 2 cm.
    • Suspected or diagnosed active intra-abdominal or perianal abscess that has not been appropriately treated.
    • Abscess located \< 2 cm in relation to the stricture.
    • Toxic megacolon.
  3. Any major surgery, in the investigator's opinion, performed within 8 weeks prior to screening or planned during the study (ie, any surgical procedure requiring general anesthesia).
  4. or history of malignancy within 5 years of the initial screening visit, except for adequately treated or completely excised nonmetastatic basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ.
  5. Diagnosis of decompensated liver disease, including but not limited to liver disease, viral hepatitis, Wilson disease, or suspected drug-induced liver injury.
  6. Liver chemistry parameters that exceed the following thresholds:

    • or AST > 2 ×
    • Alkaline phosphatase > 2.5 × ULN
    • Total > 1.5 × ULN
  7. Concomitant use of the following medications during the screening period or throughout the study:

    • Cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil within 8 weeks prior to screening.
    • Biologics (anti-tumor necrosis factor, anti-integrins, ustekinumab, or risankizumab) within 8 weeks prior to screening.
    • JAK inhibitor within 4 weeks prior to screening and throughout the study.
    • IL23p19 inhibitor within 4 weeks (or 5 half-lives, whichever is longer) prior to screening, or a history of nonresponse or intolerance to IL23p19 inhibitors.
  8. Not up-to-date with current age-appropriate vaccinations in accordance with current immunization guidelines and the investigator's usual standard of care at screening.
  9. Concurrent or previous participation in another clinical trial and received therapy within 4 weeks or 5 half-lives (whichever is longer) prior to screening.
  10. Any previous treatment with an antifibrotic therapy, including investigational antifibrotic therapies.
  11. Systemic or opportunistic infections including:

    • or or C infection. If a negative test result is available in the 12 months prior to Day 0, retesting is not required.
    • Known active or latent TB; if a negative test result is available in the 12 months prior to randomization, confirmatory testing (per standard of care) is not required before Day 0.
    • Positive stool test for Clostridioides difficile infection (as demonstrated by positive toxin).
    • Active CMV infection, as per investigator judgement
    • Other systemic or opportunistic infection, any other extraintestinal infection, infection that is not responding to standard treatment, or recurring infection within 6 months of Day 1.
  12. Known or suspected allergy, anaphylaxis, or intolerance to mirikizumab or its' .
  13. to MRE examination or suspected allergy to MRE contrast agent or antispasmodic.
  14. Prior enrolment in the current study and had received study treatment.
  15. Any acute or chronic medical condition, psychiatric disorder, or laboratory abnormality that may increase the risk associated with study participation or study intervention administration, or may interfere with the interpretation of study results, as determined by the investigator.
  16. Unwillingness to withhold protocol-prohibited medications during the trial.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Mirikizumab

    Open-label mirikizumab 900mg IV Weeks 0,4, and 8 then mirikizumab 300mg SC Weeks 12, 16, 20, and 24.

    Drug: Mirikizumab

Interventions

  • Mirikizumab is an IL-23 antagonist.

    Also known as: Omvoh

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of mirikizumab in inducing a radiologic response in participants with inflammatory stricturing CD

    Achievement of radiologic response (defined by a 25% improvement in stricture length and no worsening of prestenotic small bowel diameter or wall thickness OR 25% improvement in prestenotic small bowel diameter and no worsening of stricture length or wall thickness)

    Time frame: At week 24

Secondary outcomes

  1. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change in baseline in CDOS score

    Time frame: At week 12

  2. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in CDOS score

    Time frame: At week 24

  3. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in CDAI score

    Time frame: At week 12

  4. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in CDAI score

    Time frame: At week 24

  5. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PRO2 Score

    Time frame: At week 12

  6. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PRO2 score

    Time frame: At week 24

  7. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in HBI score

    Time frame: At week 12

  8. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in HBI score

    Time frame: At week 24

  9. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Achievement of endoscopic response (defined by ≥ 50% reduction from baseline in SES-CD score) AND radiographic improvement (defined by a ≥ 25% improvement from baseline in stricture MaRIA score)

    Time frame: At week 24

  10. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Achievement of endoscopic response (defined by ≥ 50% reduction from baseline in SES-CD score)

    Time frame: At week 24

  11. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in SIBDQ score

    Time frame: At week 24

  12. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in UNRS score

    Time frame: At week 12

  13. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in UNRS score

    Time frame: At week 24

  14. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in RHI score

    Time frame: At week 24

  15. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Achievement of histological response (defined by a ≥ 50% reduction from baseline in RHI score)

    Time frame: At week 24

  16. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Achievement of CRP response (defined by ≥ 50% reduction from baseline in CRP levels)

    Time frame: At week 12

  17. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Achievement of CRP response (defined by ≥ 50% reduction from baseline in CRP levels)

    Time frame: At week 24

  18. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in CRP level

    Time frame: At week 12

  19. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in CRP level

    Time frame: At week 24

  20. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Achievement of FCP response (defined by ≥ 50% reduction from baseline in FCP level)

    Time frame: At week 24

  21. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in FCP level

    Time frame: At week 24

  22. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PGI-S score

    Time frame: At week 4

  23. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PGI-S score

    Time frame: At week 8

  24. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PGI-S score

    Time frame: At week 12

  25. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PGI-S score

    Time frame: At week 16

  26. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PGI-S score

    Time frame: At week 20

  27. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    Change from baseline in PGI-S score

    Time frame: At week 24

  28. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    PGI-S score

    Time frame: At week 4

  29. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    PGI-S score

    Time frame: At week 8

  30. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    PGI-S score

    Time frame: At week 12

  31. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    PGI-S score

    Time frame: At week 16

  32. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    PGI-S score

    Time frame: At week 20

  33. To evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD

    PGI-S score

    Time frame: At week 24

  34. To evaluate the safety of mirikizumab in participants with stricturing CD

    Occurrence of SAEs, severe liver injury (ALT or AST ≥ 3 × ULN), and serious infections

    Time frame: Through end of safety follow-up

  35. To evaluate the safety of mirikizumab in participants with stricturing CD

    CD-related complications

    Time frame: Through end of safety follow-up defined as a composite of (1) CD-related surgery, (2) CD-related hospitalization, (3) CD-medication-related complication, and (4) rescue therapy for a documented CD-related flare

07

Study locations

5 of 8 sites recruiting
  • University of Miami
    Miami, Florida 33136, United States
    Recruiting
  • Digestive & Liver Center of Florida
    Orlando, Florida 32825, United States
    Recruiting
  • University of Chicago Medicine
    Chicago, Illinois 60637, United States
    Active, not recruiting

    Not enrolling at this site.

  • Velocity Clinical- Salt Lake City
    Salt Lake City, Utah 84088, United States
    Active, not recruiting

    Not enrolling at this site.

  • GI Institute Research Foundation
    Vancouver, British Columbia V6Z 2K5, Canada
    Recruiting
  • McMaster University Medical Center
    Hamilton, Ontario L8N 3Z5, Canada
    Recruiting
  • London Digestive Disease Institute
    London, Ontario N6K1M6, Canada
    Active, not recruiting

    Not enrolling at this site.

  • The Office of Dr. Jason Reinglas
    Scarborough Village, Ontario M1B 3V4, Canada
    Recruiting
    • Jason Reinglas · Contact
    • Jason Reinglas, Dr · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

Of 54 non-industry phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 71. This study's planned 16 months is below that.

Counting every sponsor, half of 70 studies reached it within 56 months; a quarter within 35 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
May 31, 2025
StartActual
Apr 20, 2026
Primary completionEst.
Sep 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (2 United States, 1 Canada)
  • University of Miami · Miami, United States
  • University of Chicago Medicine · Chicago, United States
  • McMaster University Medical Center · Hamilton, Canada
Oct 26, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionTo evaluate the efficacy of mirikizumab in inducing a radiologic response in participants with inflammatory stricturing CD: how it is measured was reworded
Oct 26, 2026
Secondary outcomes
21 time frame changed, 8 removed, 1 description edited, 28 more
What changed in the outcomes
  • RemovedTo evaluate the efficacy of mirikizumab in health-related quality of life in participants with inflammatory stricturing CDTime frame: At week 4
  • RemovedTo evaluate the efficacy of mirikizumab in radiologic disease activity in participants with inflammatory stricturing CDTime frame: At week 4
  • RemovedTo evaluate the efficacy of mirikizumab in endoscopic disease activity in participants with inflammatory stricturing CDTime frame: At week 4
  • RemovedTo evaluate the efficacy of mirikizumab in histologic disease activity in participants with inflammatory stricturing CDTime frame: At week 4
  • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 12
  • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 16
  • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 20
  • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDAt week 4 → At week 12
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#2At week 8 → At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#4At week 16 → At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#5At week 20 → At week 12
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#9At week 12 → At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#11At week 12 → At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#12At week 24 → At week 12
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#18At week 24 → At week 12
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#20At week 12 → At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#22At week 12 → At week 4
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#23At week 24 → At week 8
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#24At week 24 → At week 12
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#25At week 24 → At week 16
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#26At week 4 → At week 20
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#27At week 8 → At week 24
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#28At week 12 → At week 4
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#29At week 16 → At week 8
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#30At week 20 → At week 12
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#31At week 24 → At week 16
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#32At week 4 → At week 20
  • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#33At week 8 → At week 24
  • DescriptionTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD: how it is measured was reworded
  • …and 28 more, on the record history on ClinicalTrials.gov ↗
Oct 26, 2026
Contact
Study contact changed: a•••@alimentiv.com · •••3688→a•••@alimentiv.com · •••2282. See the current contact
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    3 sites added
    Show 3 added (2 United States, 1 Canada)
    • University of Miami · Miami, United States
    • University of Chicago Medicine · Chicago, United States
    • McMaster University Medical Center · Hamilton, Canada
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionTo evaluate the efficacy of mirikizumab in inducing a radiologic response in participants with inflammatory stricturing CD: how it is measured was reworded
    Secondary outcomes 21 time frame changed, 8 removed, 1 description edited, 28 more
    What changed in the outcomes
    • RemovedTo evaluate the efficacy of mirikizumab in health-related quality of life in participants with inflammatory stricturing CDTime frame: At week 4
    • RemovedTo evaluate the efficacy of mirikizumab in radiologic disease activity in participants with inflammatory stricturing CDTime frame: At week 4
    • RemovedTo evaluate the efficacy of mirikizumab in endoscopic disease activity in participants with inflammatory stricturing CDTime frame: At week 4
    • RemovedTo evaluate the efficacy of mirikizumab in histologic disease activity in participants with inflammatory stricturing CDTime frame: At week 4
    • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 12
    • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 16
    • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 20
    • RemovedTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDTime frame: At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CDAt week 4 → At week 12
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#2At week 8 → At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#4At week 16 → At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#5At week 20 → At week 12
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#9At week 12 → At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#11At week 12 → At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#12At week 24 → At week 12
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#18At week 24 → At week 12
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#20At week 12 → At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#22At week 12 → At week 4
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#23At week 24 → At week 8
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#24At week 24 → At week 12
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#25At week 24 → At week 16
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#26At week 4 → At week 20
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#27At week 8 → At week 24
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#28At week 12 → At week 4
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#29At week 16 → At week 8
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#30At week 20 → At week 12
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#31At week 24 → At week 16
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#32At week 4 → At week 20
    • Time frameTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD#33At week 8 → At week 24
    • DescriptionTo evaluate the efficacy of mirikizumab in improving symptoms in participants with inflammatory stricturing CD: how it is measured was reworded
    • …and 28 more, on the record history on ClinicalTrials.gov ↗
    Contact Study contact changed: a•••@alimentiv.com · •••3688→a•••@alimentiv.com · •••2282. See the current contact
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06997965
Lead sponsor
Alimentiv Inc.
Responsible party
Sponsor
First posted
May 31, 2025
Start date
Apr 20, 2026
Primary completion
Sep 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Jennifer Earle
Contact
jennifer.earle@alimentiv.com
Ashley Jackson
Contact
ashley.jackson@alimentiv.com
226-666-2282

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion